TwinBeech Capital’s SpringWorks Therapeutics SWTX Stock Holding History

TwinBeech Capital’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-138,234	Closed	-$4.43M	–	917
2024 Q3	$4.43M	Buy	138,234 +51,176	+59%	+$1.91M	0.08%	276
2024 Q2	$3.28M	Sell	87,058 -4,842	-5%	-$204K	0.06%	273
2024 Q1	$4.52M	Buy	+91,900	New	+$4.25M	0.09%	226
2023 Q4	–	Sell	-122,429	Closed	-$2.83M	–	897
2023 Q3	$2.83M	Buy	+122,429	New	+$3.35M	0.05%	356
2023 Q2	–	Sell	-56,658	Closed	-$1.46M	–	849
2023 Q1	$1.46M	Buy	+56,658	New	+$1.66M	0.03%	414
2022 Q1	–	Sell	-18,599	Closed	-$1.15M	–	731
2021 Q4	$1.15M	Buy	18,599 +14,420	+345%	+$954K	0.07%	322
2021 Q3	$265K	Buy	+4,179	New	+$322K	0.02%	514

Other funds holding SWTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

TwinBeech Capital's SWTX Position: Q4 2024 in Review

TwinBeech Capital sold out of SpringWorks Therapeutics (SWTX) in Q4 2024, closing a stake of 138,234 shares — an estimated $4.43M sold.

TwinBeech Capital first reported a position in SWTX in Q3 2021 and held it in 7 quarters. The position peaked at $4.52M in Q1 2024. 216 funds tracked by Wall St. Rank hold SWTX as of Q4 2024.

TwinBeech Capital reported no remaining SpringWorks Therapeutics position as of Q4 2024 after selling out during the quarter.
TwinBeech Capital sold 138,234 SpringWorks Therapeutics shares in Q4 2024, an estimated $4.43M.
TwinBeech Capital first reported a position in SpringWorks Therapeutics in Q3 2021 and held it in 7 quarters.
TwinBeech Capital's SpringWorks Therapeutics position peaked at $4.52M in Q1 2024.
216 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q4 2024.

Based on TwinBeech Capital's 13F filing for Q4 2024, filed 14 Feb 2025.